Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant carboplatin-based chemoradiation followed by carboplatin + paclitaxel for high-risk endometrial carcinoma
ACTRN12605000561684Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in endometrial cancer (EC), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Progression-free survival. Started Jun 2004; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ACTRN12605000561684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000561684.